164 related articles for article (PubMed ID: 38202821)
1. Suberoylanilide Hydroxamic Acid Analogs with Heteroaryl Amide Group and Different Chain Length: Synthesis and Effect on Histone Deacetylase.
Micheletti G; Boga C; Drius G; Bordoni S; Calonghi N
Molecules; 2024 Jan; 29(1):. PubMed ID: 38202821
[TBL] [Abstract][Full Text] [Related]
2. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
3. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC /microRNA regulation.
Mekala JR; Ramalingam PS; Mathavan S; Yamajala RBRD; Moparthi NR; Kurappalli RK; Manyam RR
Chem Biol Interact; 2022 Apr; 357():109876. PubMed ID: 35283086
[TBL] [Abstract][Full Text] [Related]
5. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
6. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
[TBL] [Abstract][Full Text] [Related]
7. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
Carbajo-García MC; García-Alcázar Z; Corachán A; Monleón J; Trelis A; Faus A; Pellicer A; Ferrero H
Fertil Steril; 2022 Feb; 117(2):433-443. PubMed ID: 34809976
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
10. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
Choi SE; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication.
Saha B; Parks RJ
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944181
[TBL] [Abstract][Full Text] [Related]
12. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
Choi SE; Pflum MK
Bioorg Med Chem Lett; 2012 Dec; 22(23):7084-6. PubMed ID: 23089527
[TBL] [Abstract][Full Text] [Related]
13. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
Desai D; Salli U; Vrana KE; Amin S
Bioorg Med Chem Lett; 2010 Mar; 20(6):2044-7. PubMed ID: 20167479
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Improves Energetic Status and Cardiomyogenic Differentiation of Human Dilated Myocardium-Derived Primary Mesenchymal Cells.
Miksiunas R; Rucinskas K; Janusauskas V; Labeit S; Bironaite D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650632
[TBL] [Abstract][Full Text] [Related]
16. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
[TBL] [Abstract][Full Text] [Related]
17. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
Hendricks JA; Keliher EJ; Marinelli B; Reiner T; Weissleder R; Mazitschek R
J Med Chem; 2011 Aug; 54(15):5576-82. PubMed ID: 21721525
[TBL] [Abstract][Full Text] [Related]
18. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network.
Sardiu ME; Smith KT; Groppe BD; Gilmore JM; Saraf A; Egidy R; Peak A; Seidel CW; Florens L; Workman JL; Washburn MP
Mol Cell Proteomics; 2014 Nov; 13(11):3114-25. PubMed ID: 25073741
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Natural Flavonoid Curcumin Exhibits Anticancer and Antibacterial Activity.
Altundağ EM; Toprak K; Şanlıtürk G; Güran M; Özbilenler C; Kerküklü NR; Yılmaz AM; Yalçın AS
Anticancer Agents Med Chem; 2021; 21(10):1301-1308. PubMed ID: 33023457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
